Literature DB >> 26162329

Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Lynch Syndrome and Associated Endometrial Cancer.

Laura J Tafe1.   

Abstract

Lynch syndrome is a hereditary cancer syndrome that results from germline mutations in one of the DNA mismatch repair genes, leading to an increased lifetime risk of cancer. Colorectal cancer is most commonly identified with Lynch syndrome; however, women with Lynch syndrome have an increased risk of developing endometrial cancer (up to 60%), which is the sentinel diagnosis in approximately one-half of the cases. Current screening algorithms are developed on family history and laboratory-based tests, including immunohistochemistry for mismatch repair proteins and microsatellite instability testing. Next-generation sequencing assays are rapidly being incorporated into clinical laboratory practices and have diagnostic applications for hereditary cancer syndromes. Important challenges of next-generation sequencing include interpreting incidental and uncertain findings, counseling before and after testing, and informed consent of patients. Here, with the use of Lynch syndrome in endometrial cancer as a model, some of the applications and intricacies of next-generation sequencing testing for hereditary cancer syndromes are reviewed.
Copyright © 2015 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26162329     DOI: 10.1016/j.jmoldx.2015.06.001

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  8 in total

Review 1.  Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

Authors:  Valerie Lee; Adrian Murphy; Dung T Le; Luis A Diaz
Journal:  Oncologist       Date:  2016-07-13

2.  Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.

Authors:  Gai Elhanan; Daniel Kiser; Iva Neveux; Shaun Dabe; Alexandre Bolze; William J Metcalf; James T Lu; Joseph J Grzymski
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

Review 3.  Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome.

Authors:  Gergely Buglyó; Jakub Styk; Ondrej Pös; Ádám Csók; Vanda Repiska; Beáta Soltész; Tomas Szemes; Bálint Nagy
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

Review 4.  Surgical treatment of high stage endometrial cancer: current perspectives.

Authors:  Salvatore Giovanni Vitale; Gaetano Valenti; Ferdinando Antonio Gulino; Pietro Cignini; Antonio Biondi
Journal:  Updates Surg       Date:  2016-01-29

5.  Understanding Molecular Landscape of Endometrial Cancer through Next Generation Sequencing: What We Have Learned so Far?

Authors:  Siti-Syazani Suhaimi; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2016-11-01       Impact factor: 5.810

6.  Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.

Authors:  Lídia Feliubadaló; Raúl Tonda; Mireia Gausachs; Jean-Rémi Trotta; Elisabeth Castellanos; Adriana López-Doriga; Àlex Teulé; Eva Tornero; Jesús Del Valle; Bernat Gel; Marta Gut; Marta Pineda; Sara González; Mireia Menéndez; Matilde Navarro; Gabriel Capellá; Ivo Gut; Eduard Serra; Joan Brunet; Sergi Beltran; Conxi Lázaro
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

7.  A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?

Authors:  Neil A J Ryan; Niall J Davison; Katherine Payne; Anne Cole; D Gareth Evans; Emma J Crosbie
Journal:  Front Oncol       Date:  2019-02-26       Impact factor: 6.244

8.  A new mutL homolog 1 c.1896+5G>A germline mutation detected in a Lynch syndrome-associated lung and gastric double primary cancer patient.

Authors:  Xuyuan Chen; Xiang Li; Hongsen Liang; Lichun Wei; Qiang Cui; Ming Yao; Xu Wu
Journal:  Mol Genet Genomic Med       Date:  2019-06-17       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.